Jul 24, 2019 9:25 am EDT Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 7, 2019 8:39 am EST Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
Apr 9, 2018 8:00 am EDT Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Apr 4, 2018 8:00 am EDT Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
Dec 26, 2017 11:41 am EST UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
Dec 7, 2017 8:30 am EST AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
Oct 17, 2017 8:00 am EDT AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
